Remicade monotherapy approved for psoriatic arthritis

The monoclonal antibody, Remicade (infliximab) has been approved for use as monotherapy in the treatment of active and progressive psoriatic arthritis that has responded inadequately to disease-modifying anti-rheumatic drugs in patients where methotrexate is contraindicated or not tolerated.

Previously, Remicade was licensed only for use in combination with methotrexate to treat the condition.
The recommended dosage is 5mg/kg by intravenous infusion over a two-hour period, repeated two and six weeks after the first infusion and then every six to eight weeks.

Further information: Schering-Plough Ltd, Schering-Plough House, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW. Tel: (01707) 363636.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...